

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 May 12	EXTEND option available in structure searching
NEWS	4 May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5 May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus
NEWS	6 May 27	CPlus super roles and document types searchable in REGISTRY
NEWS	7 Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8 Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9 Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10 Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11 AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12 AUG 02	CPlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13 AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14 AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15 AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16 AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17 AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18 SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19 SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20 SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:27:03 ON 02 SEP 2004

=> file caplus uspatful japio medline europatful biosis embase scisearch		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:27:51 ON 02 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:27:51 ON 02 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:27:51 ON 02 SEP 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'MEDLINE' ENTERED AT 15:27:51 ON 02 SEP 2004

FILE 'EUROPATFULL' ENTERED AT 15:27:51 ON 02 SEP 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 15:27:51 ON 02 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 15:27:51 ON 02 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:27:51 ON 02 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

=> (COPD or (chronic obstructive pulmonary disorder))
(COPD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (COPD or (chronic obstructive pulmonary disorder))
L1 33114 (COPD OR (CHRONIC OBSTRUCTIVE PULMONARY DISORDER))

=> s l1 and (treatment or therap? or prophyla?)
7 FILES SEARCHED...
L2 16920 L1 AND (TREATMENT OR THERAP? OR PROPHYLA?)

=> s l2 and (nicotin?)
L3 445 L2 AND (NICOTIN?)

=> s l3 and (systemic? or oral? or transdermal? or intravascular? or intravaginal?)
L4 352 L3 AND (SYSTEMIC? OR ORAL? OR TRANSDERMAL? OR INTRAVASCULAR?
OR INTRAVAGINAL?)

=> s l4 and emphysema
L5 186 L4 AND EMPHYSEMA

=> s l5 and asthma
L6 176 L5 AND ASTHMA

=> s l6 and nicotine
L7 41 L6 AND NICOTINE

=> s 17 and intranasal?
L8 14 L7 AND INTRANASAL?

=> d 18 1-4 ibib abs

L8 ANSWER 1 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:114048 USPATFULL
TITLE: Drug metabolizing enzymes
INVENTOR(S): Azimzai, Yalda, Oakland, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Borowsky, Mark L, Redwood City, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Nguyen, Dannel B, San Jose, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Policky, Jennifer L, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Ring, Huizun Z, Foster City, CA, UNITED STATES
Sanjanwala, Madhusudan M, San Jose, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Walsh, Roderick T, Canterbury, UNITED KINGDOM
Warren, Bridget A, Encinitas, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004086887	A1	20040506
APPLICATION INFO.:	US 2003-381898	A1	20030327 (10)
	WO 2001-US30662		20010928
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	91		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8244		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of DME.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:64276 USPATFULL

TITLE: Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
INVENTOR(S): Ivanova, Svetlana M., Astoria, NY, UNITED STATES
Tracey, Kevin J., Old Greenwich, CT, UNITED STATES
PATENT ASSIGNEE(S): North Shore-Long Island Jewish Research Institute, Manhasset, NY, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048795	A1	20040311
APPLICATION INFO.:	US 2003-375696	A1	20030226 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360082P	20020226 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for inhibiting pro-inflammatory cytokine release or inflammation in a vertebrate are provided. The methods comprise activating a brain muscarinic receptor of the vertebrate, or directly stimulating a vagus nerve pathway in the brain of the vertebrate. Also provided are methods for conditioning a vertebrate to inhibit the release of a pro-inflammatory cytokine or reduce inflammation in the vertebrate upon experiencing a sensory stimulus. The methods comprise (a) activating a muscarinic brain receptor or directly stimulating the vagus nerve pathway in the brain of the vertebrate and providing the sensory stimulus to the vertebrate within a time period sufficient to create an association between the stimulus and the activation of the brain muscarinic receptor; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the inflammation to be reduced by the sensory stimulus alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:38593 USPATFULL
TITLE: Drug metabolizing enzymes
INVENTOR(S): Yue, Henry, Sunnyvale, CA, UNITED STATES
Sanjanwala, Madhusudan M., Los Altos, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Gandhi, Ameena R., Menlo Park, CA, UNITED STATES
Ring, Huijin Z., Los Altos, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Chawla, Narinder K., San Leandro, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Khan, Farrah A., Glenview, IL, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Tang, Y. tom, San Jose, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Nguyen, Danniel B., San Jose, CA, UNITED STATES
Yao, Monique G., Mountain View, CA, UNITED STATES
Lee, Ernestine A., Albany, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Arvizu, Chandra S., Menlo Park, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES

Burford, Neil, Durham, CT, UNITED STATES
Ding, Li, Palo Alto, CA, UNITED STATES
Bruns, Christopher M., Mountain View, CA, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Reddy, Roopa M., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029132	A1	20040212
APPLICATION INFO.:	US 2003-296606	A1	20030502 (10)
	WO 2001-US17150		20010525
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7800		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with aberrant expression of DME.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated

polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 5-14 ibib abs

L8 ANSWER 5 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:7345 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and **therapeutic** methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:4504 USPATFULL
TITLE: Tumor necrosis factor receptor 2
INVENTOR(S): Stanton, Jr., Vincent P., Belmont, MA, United States
PATENT ASSIGNEE(S): Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673908	B1	20040106
APPLICATION INFO.:	US 2001-968455		20011001 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-649035, filed on 25 Aug 2000 Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on 1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US 2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252, filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on 9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US 1999-300747, filed on 26 Apr 1999, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131334P	19990426 (60)
	US 1999-131191P	19990426 (60)
	US 1999-121047P	19990222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Benzion, Gary	
ASSISTANT EXAMINER:	Chakrabarti, Arun Kr.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	17463	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of **treatment**. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:265964 USPATFULL
TITLE: Benzamide, heteroarylamide and reverse amides
INVENTOR(S): Duplantier, Allen J., Ledyard, CT, UNITED STATES
Subramanyam, Chakrapani, South Glastonbury, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003186981 A1 20031002
 APPLICATION INFO.: US 2002-292887 A1 20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336781P	20011112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3263	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel to P2X.sub.7 inhibitors of
 formula I ##STR1##

and to processes for their preparation, intermediates useful in their
 preparation, pharmaceutical compositions containing them, and their use
 in **therapy**. The active compounds of the present invention are
 potent inhibitors of P2X.sub.7 and as such are useful in the
treatment of inflammation, osteoarthritis, rheumatoid arthritis,
 cancer, reperfusion or ischemia in stroke or heart attack, autoimmune
 diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:265887 USPATFULL
 TITLE: Keratinocyte growth factor-2
 INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
 Jimenez, Pablo, Chatham, NJ, UNITED STATES
 Duan, Roxanne D., Bethesda, MD, UNITED STATES
 Rampy, Mark A., Montgomery Village, MD, UNITED STATES
 Mendrick, Donna, Mount Airy, MD, UNITED STATES
 Zhang, Jun, Bethesda, MD, UNITED STATES
 Ni, Jian, Rockville, MD, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
 Gruber, Joachim R., Elizabethtown, KY, UNITED STATES
 Dillon, Patrick J., Carlsbad, CA, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186904	A1	20031002
APPLICATION INFO.:	US 2002-35212	A1	20020104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-259853P	20010108 (60)
	US 2001-286368P	20010426 (60)
	US 2001-331168P	20011109 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	64 Drawing Page(s)	
LINE COUNT:	17177	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the **therapeutic** use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:207932 USPATFULL
TITLE: N-alkyl-adamantyl triazinyl benzamide derivatives
INVENTOR(S): Duplantier, Allen J., Ledyard, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144293	A1	20030731
APPLICATION INFO.:	US 2002-292886	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336892P	20011112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2342	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formula I ##STR1##

and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in **therapy**. The active compounds of the present invention are useful in the **treatment** of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:173153 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118997	A1	20030626
APPLICATION INFO.:	US 2001-978418	A1	20011015 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-311305P	20010810 (60)

US 2001-314734P 20010824 (60)
US 2001-318204P 20010907 (60)
US 2001-326470P 20011001 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Saliwanchik, Lloyd & Saliwanchik, Frank C. Eisenchenk,
Ph. D, 2421 N.W. 41st street, Suite A-1, Gainesville,
FL, 32606-6669

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 15316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:160075 USPATFULL
TITLE: Colon and colon cancer associated polynucleotides and polypeptides
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 17981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and

therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:113075 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077808	A1	20030424
APPLICATION INFO.:	US 2001-764891	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 59131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and **therapeutic** methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 14 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1310493 EUROPATFULL EW 200320 FS OS
TITLE: N-adamantylalkyl benzamide derivatives as p2x7-receptor antagonists.
N-Adamantylalkyl Benzamide Derivativen als p2x7-rezeptor antagonisten.
Derives de la (N-adamantylalkyl)-benzamide comme antagonistes des recepteurs p2x7.
INVENTOR(S): Duplantier, Allen J., Pfizer Global Res. & Dev., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE(S): Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE NO: 2434221
AGENT: Motion, Keith Robert et al., Pfizer Limited Patents Department Ramsgate Road, Sandwich, Kent CT13 9NJ, GB 91141
AGENT NUMBER:
OTHER SOURCE: MEPA2003038 EP 1310493 A1 0039
SOURCE: Wila-EPZ-2003-H20-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1310493	A1 20030514
'OFFENLEGUNGS' DATE:		20030514
APPLICATION INFO.:	EP 2002-257719	20021107
PRIORITY APPLN. INFO.:	US 2001-336892	20011112

L8 ANSWER 14 OF 14 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 1998089448 EMBASE
TITLE: Strategies in preserving lung health and preventing COPD and associated diseases: The National Lung Health Education Program (NLHEP).
AUTHOR: Bailey W.C.; Ferguson G.T.; Higgins M.; Hudson L.D.; Miller R.D.; Masferrer R.; Nair S.; Rennard S.I.; Petty T.L.; Shure D.; Hindi-Alexander M.; Weinmann G.; Hurd S.S.
SOURCE: Chest, (1998) 113/2 SUPPL. (123S-163S).
Refs: 156
ISSN: 0012-3692 CODEN: CHETBF
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
017 Public Health, Social Medicine and Epidemiology
036 Health Policy, Economics and Management
037 Drug Literature Index
LANGUAGE: English

=> d 18 14 full

'FULL' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):all

L8 ANSWER 14 OF 14 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 1998089448 EMBASE
TI Strategies in preserving lung health and preventing COPD and
associated diseases: The National Lung Health Education Program (NLHEP).
AU Bailey W.C.; Ferguson G.T.; Higgins M.; Hudson L.D.; Miller R.D.;
Masferrer R.; Nair S.; Rennard S.I.; Petty T.L.; Shure D.; Hindi-Alexander
M.; Weinmann G.; Hurd S.S.
SO Chest, (1998) 113/2 SUPPL. (123S-163S).
Refs: 156
ISSN: 0012-3692 CODEN: CHETBF
CY United States
DT Journal; General Review
FS 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
017 Public Health, Social Medicine and Epidemiology
036 Health Policy, Economics and Management
037 Drug Literature Index
LA English
CT Medical Descriptors:
*chronic obstructive lung disease: DI, diagnosis
*chronic obstructive lung disease: DT, drug therapy
*chronic obstructive lung disease: EP, epidemiology
*chronic obstructive lung disease: ET, etiology
*chronic obstructive lung disease: PC, prevention
*chronic obstructive lung disease: RH, rehabilitation
*chronic obstructive lung disease: TH, therapy
*asthma: DI, diagnosis
*asthma: DT, drug therapy
*asthma: EP, epidemiology
*asthma: ET, etiology
*asthma: PC, prevention
*asthma: RH, rehabilitation
*asthma: TH, therapy
*chronic bronchitis: DI, diagnosis
*chronic bronchitis: DT, drug therapy
*chronic bronchitis: EP, epidemiology
*chronic bronchitis: ET, etiology
*chronic bronchitis: PC, prevention
*chronic bronchitis: RH, rehabilitation
*chronic bronchitis: TH, therapy
*lung emphysema: DI, diagnosis
*lung emphysema: DT, drug therapy
*lung emphysema: ET, etiology
*lung emphysema: PC, prevention
*lung emphysema: RH, rehabilitation
*lung emphysema: TH, therapy
health program
health care policy
treatment planning
primary prevention
primary medical care
clinical feature
risk factor
pathophysiology
mortality
morbidity
socioeconomics
cigarette smoking
early diagnosis
spirometry

thorax radiography
patient education
smoking cessation
drug choice
oxygen therapy
human
oral drug administration
transdermal drug administration
intranasal drug administration
inhalational drug administration
review
priority journal

Drug Descriptors:

*cholinergic receptor blocking agent: DT, drug therapy
*bronchodilating agent: DT, drug therapy
*nicotine gum
*amfebutamone
*corticosteroid: DT, drug therapy
*mucolytic agent: DT, drug therapy
theophylline: DO, drug dose
theophylline: DT, drug therapy
prednisone: DO, drug dose
prednisone: DT, drug therapy
atropine: DT, drug therapy
ipratropium bromide: DT, drug therapy
guaifenesin: DT, drug therapy
antibiotic agent: DT, drug therapy
acetylcysteine: DT, drug therapy
proteinase inhibitor: DT, drug therapy
antioxidant: DT, drug therapy

RN (nicotine gum) 96055-45-7; (amfebutamone) 31677-93-7,
34911-55-2; (theophylline) 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1,
99007-19-9; (prednisone) 53-03-2; (atropine) 51-55-8, 55-48-1;
(ipratropium bromide) 22254-24-6; (guaifenesin) 93-14-1; (acetylcysteine)
616-91-1; (proteinase inhibitor) 37205-61-1

=> d 18 14 ab

L8 ANSWER 14 OF 14 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003397789 EMBASE
TITLE: Management of **COPD** according to guidelines. A
national survey among Belgian physicians.
AUTHOR: Decramer M.; Bartsch P.; Pauwels R.; Yernault J.C.; Bruart
J.; Buffels J.; Cnockaert P.; Coolen D.; De Backer W.;
Degives R.; Degryse J.M.; Demedts M.; Derom E.; De Vuyst
P.; Dewaele R.; Diels R.; Dierckx J.P.; Garzaniti N.; Gepts
L.; Gillard C.; Haenebalcke C.; Heyrman J.; Hoengenaert
J.P.; Louis R.; Marchand E.; Meysman M.; Minguet C.;
Pestiaux D.; Robience Y.; Rodenstein D.; Sergysels R.; Van
Bragt J.; Vander Elst B.; Vermeire P.; Vincken W.
CORPORATE SOURCE: Prof. Dr. M. Decramer, Respiratory Division, University
Hospital, Katholieke Universiteit Leuven, Herestraat 49,
B-3000 Leuven, Belgium
SOURCE: Monaldi Archives for Chest Disease, (2003) 59/1 (62-80).
Refs: 40
ISSN: 1122-0643 CODEN: MACDEL
COUNTRY: Italy
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
037 Drug Literature Index
017 Public Health, Social Medicine and Epidemiology
019 Rehabilitation and Physical Medicine
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Current management of **COPD** by Belgian physicians was compared
with the recommendations of the recently published GOLD guidelines. A
random sample of 386 general practitioners and 86 pulmonologists filled in
a questionnaire based on the GOLD guidelines and examining their attitudes
towards **COPD** management. Several important deviations from the
guidelines were noted. Only few GP's performed spirometry themselves and
about 55% of the diagnoses were not based on spirometry. Both GP's and
pulmonologists used inhaled corticosteroids considerably more often than
prescribed by the guidelines, with 49% and 25% respectively, prescribing
them to all **COPD** patients. Chronic systemic steroids were also
overused in stable disease, with 55% of the GP's and 52% of the
pulmonologists prescribing them in patients with repeated exacerbations.
GP's did not use enough systemic corticosteroids and overused antibiotics
in the **treatment** of exacerbations. Pulmonologists did not pay
enough attention to pulmonary rehabilitation, as only 44% of them had a
structured programme. Pulmonologists did not use non-invasive ventilation
frequently enough in the **treatment** of exacerbations, as only 22%
would use it in the correct indication. Both GP's and pulmonologists did
not prescribe enough pharmacotherapy for smoking cessation, with 35% and
46%, respectively using it. Some interesting differences between Dutch and
French speaking physicians were noted. These specific deviations from the
guidelines will be addressed in a second phase implementation project.

=> s emphysema and nicotine
L15 522 EMPHYSEMA AND NICOTINE

=> s l15 and (treat? or therap? or prophyla?)
7 FILES SEARCHED...

L16 363 L15 AND (TREAT? OR THERAP? OR PROPHYLA?)

=> s l16 and intransal?
<-----User Break----->

SEARCH ENDED BY USER

=> s l16 and intranasal?
L17 117 L16 AND INTRANASAL?

=> s l17 and oral?
L18 117 L17 AND ORAL?

=> s l18 and (transdermal? or percutaneous?)
L19 80 L18 AND (TRANSDERMAL? OR PERCUTANEOUS?)

=> s l19 and intravascular?
L20 16 L19 AND INTRAVASCULAR?

=> d l20 1-16 ibib abs

L20 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:167808 CAPLUS

DOCUMENT NUMBER: 134:212742

TITLE: Use of at least one substance based on
nicotine and/or a substance produced from said
one substance for the manufacture of a medicament for
treatment of obstructive lung diseases

INVENTOR(S): Bense, Laszlo

PATENT ASSIGNEE(S): Swed.

SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015697	A1	20010308	WO 2000-SE1683	20000901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
SE 9903085	A	20010302	SE 1999-3085	19990901
SE 516807	C2	20020305		
EP 1207883	A1	20020529	EP 2000-959096	20000901
R: AT, BE, CH, DE, DK, ES, FR, GB, LI, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			SE 1999-3085	A 19990901
			SE 2000-1075	A 20000327
			WO 2000-SE1683	W 20000901
AB The invention refers to a use of at least one substance based on				

nicotine and/or a substance produced from said one substance for the manufacture of a medicament to be supplied to an individual of a human being or an animal for the purpose of counteracting, in a prophylactic or therapeutic manner, obstructive lung diseases, in particular pulmonary emphysema. A suitable dosing for obtaining the desired effect is 1-100 mg/24 h of nicotine. The medicament is intended to be supplied via the blood path and to be administered via the gastrointestinal tract, transdermally, intravascularly, intranasally or intravaginally. The invention also refers to a method for prophylactic or therapeutic treatment of obstructive lung diseases of an individual of a human being or an animal, wherein said individual is supplied with a nicotine-based substance.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:41451 USPATFULL

TITLE: Keratinocyte growth factor-2

INVENTOR(S): Ruben, Steven M., Brookeville, MD, United States
Jimenez, Pablo, Chatham, NJ, United States
Duan, D. Roxanne, Gaithersburg, MD, United States
Rampy, Mark A., Montgomery Village, MD, United States
Mendrick, Donna, Mount Airy, MD, United States
Zhang, Jun, San Diego, CA, United States
NI, Jian, Germantown, MD, United States
Moore, Paul A., North Bethesda, MD, United States
Coleman, Timothy A., Gaithersburg, MD, United States
Gruber, Joachim R., Dallas, TX, United States
Dillon, Patrick J., Carlsbad, CA, United States
Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693077	B1	20040217
APPLICATION INFO.:	US 2000-610651		20000630 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-345373, filed on 1 Jul 1999 Continuation of Ser. No. US 1998-23082, filed on 13 Feb 1998, now patented, Pat. No. US 6077692 Continuation-in-part of Ser. No. US 1997-910875, filed on 13 Aug 1997 Continuation-in-part of Ser. No. US 1997-862432, filed on 23 May 1997 Division of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995 Continuation-in-part of Ser. No. US 610651 Continuation-in-part of Ser. No. US 1996-696135, filed on 13 Aug 1996 Continuation-in-part of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205417P	20000519 (60)
	US 2000-198322P	20000419 (60)
	US 1999-171677P	19991222 (60)
	US 1999-163375P	19991103 (60)
	US 1999-149935P	19990819 (60)
	US 1999-148628P	19990812 (60)
	US 1999-144024P	19990715 (60)
	US 1999-143648P	19990714 (60)
	US 1999-142343P	19990702 (60)

US 1997-39045P 19970228 (60)
US 1997-55561P 19970813 (60)
US 1996-23852P 19960813 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saoud, Christine J.
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 80 Drawing Figure(s); 64 Drawing Page(s)
LINE COUNT: 16222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the **therapeutic** use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 16 USPTFULL on STN

ACCESSION NUMBER: 2004:12971 USPTFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, **treating**, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or

prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, **treating**, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:282611 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE

PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198954	A1	20031023
APPLICATION INFO.:	US 2001-1142	A1	20011114 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	25681	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:265887 USPATFULL

TITLE: Keratinocyte growth factor-2

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Jimenez, Pablo, Chatham, NJ, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Rampy, Mark A., Montgomery Village, MD, UNITED STATES
Mendrick, Donna, Mount Airy, MD, UNITED STATES
Zhang, Jun, Bethesda, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Gruber, Joachim R., Elizabethtown, KY, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186904	A1	20031002
APPLICATION INFO.:	US 2002-35212	A1	20020104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-259853P	20010108 (60)
	US 2001-286368P	20010426 (60)
	US 2001-331168P	20011109 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW
YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC,
20005-3934

NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 64 Drawing Page(s)
LINE COUNT: 17177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the **therapeutic** use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 7 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:244219 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170628	A1	20030911
APPLICATION INFO.:	US 2001-999570	A1	20011114 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25549

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 8 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:231986 USPATFULL
 TITLE: Human cDNAs and proteins and uses thereof
 INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162186	A1	20030828
APPLICATION INFO.:	US 2002-154678	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293574P	20010525 (60)
	US 2001-298698P	20010615 (60)
	US 2001-302277P	20010629 (60)
	US 2001-305456P	20010713 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
 ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
 GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 25533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such
 GENSET products may be used as reagents in forensic analyses, as
 chromosome markers, as tissue/cell/organelle-specific markers, in the
 production of expression vectors. In addition, they may be used in
 screening and diagnosis assays for abnormal GENSET expression and/or
 biological activity and for screening compounds that may be used in the
 treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 9 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:225673 USPATFULL
 TITLE: Human cDNAs and proteins and uses thereof
 INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157485	A1	20030821
APPLICATION INFO.:	US 2001-992095	A1	20011113 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
 ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
 GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25484

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:173153 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118997	A1	20030626
APPLICATION INFO.:	US 2001-978418	A1	20011015 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-311305P	20010810 (60)
	US 2001-314734P	20010824 (60)
	US 2001-318204P	20010907 (60)
	US 2001-326470P	20011001 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Saliwanchik, Lloyd & Saliwanchik, Frank C. Eisenchenk, Ph. D, 2421 N.W. 41st street, Suite A-1, Gainesville, FL, 32606-6669	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15316	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:160075 USPATFULL
TITLE: Colon and colon cancer associated polynucleotides and polypeptides
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 17981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the colon, including colon cancer, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 12 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:140406 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096247	A1	20030522
APPLICATION INFO.:	US 2001-986	A1	20011114 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento
Valley Road, San Diego, CA, 92121-1609

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such
GENSET products may be used as reagents in forensic analyses, as
chromosome markers, as tissue/cell/organelle-specific markers, in the
production of expression vectors. In addition, they may be used in
screening and diagnosis assays for abnormal GENSET expression and/or
biological activity and for screening compounds that may be used in the
treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 13 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:133926 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092011	A1	20030515
APPLICATION INFO.:	US 2001-489	A1	20011114 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento
Valley Road, San Diego, CA, 92121-1609

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25607

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such
GENSET products may be used as reagents in forensic analyses, as
chromosome markers, as tissue/cell/organelle-specific markers, in the
production of expression vectors. In addition, they may be used in
screening and diagnosis assays for abnormal GENSET expression and/or
biological activity and for screening compounds that may be used in the
treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 14 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:113075 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077808	A1	20030424	
APPLICATION INFO.:	US 2001-764891	A1	20010117	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-179065P	20000131	(60)
	US 2000-180628P	20000204	(60)
	US 2000-214886P	20000628	(60)
	US 2000-217487P	20000711	(60)
	US 2000-225758P	20000814	(60)
	US 2000-220963P	20000726	(60)
	US 2000-217496P	20000711	(60)
	US 2000-225447P	20000814	(60)
	US 2000-218290P	20000714	(60)
	US 2000-225757P	20000814	(60)
	US 2000-226868P	20000822	(60)
	US 2000-216647P	20000707	(60)
	US 2000-225267P	20000814	(60)
	US 2000-216880P	20000707	(60)
	US 2000-225270P	20000814	(60)
	US 2000-251869P	20001208	(60)
	US 2000-235834P	20000927	(60)
	US 2000-234274P	20000921	(60)
	US 2000-234223P	20000921	(60)
	US 2000-228924P	20000830	(60)
	US 2000-224518P	20000814	(60)
	US 2000-236369P	20000929	(60)
	US 2000-224519P	20000814	(60)
	US 2000-220964P	20000726	(60)
	US 2000-241809P	20001020	(60)
	US 2000-249299P	20001117	(60)
	US 2000-236327P	20000929	(60)
	US 2000-241785P	20001020	(60)
	US 2000-244617P	20001101	(60)
	US 2000-225268P	20000814	(60)
	US 2000-236368P	20000929	(60)
	US 2000-251856P	20001208	(60)
	US 2000-251868P	20001208	(60)
	US 2000-229344P	20000901	(60)
	US 2000-234997P	20000925	(60)
	US 2000-229343P	20000901	(60)
	US 2000-229345P	20000901	(60)
	US 2000-229287P	20000901	(60)
	US 2000-229513P	20000905	(60)
	US 2000-231413P	20000908	(60)
	US 2000-229509P	20000905	(60)
	US 2000-236367P	20000929	(60)
	US 2000-237039P	20001002	(60)
	US 2000-237038P	20001002	(60)
	US 2000-236370P	20000929	(60)
	US 2000-236802P	20001002	(60)
	US 2000-237037P	20001002	(60)
	US 2000-237040P	20001002	(60)
	US 2000-240960P	20001020	(60)
	US 2000-239935P	20001013	(60)
	US 2000-239937P	20001013	(60)
	US 2000-241787P	20001020	(60)
	US 2000-246474P	20001108	(60)
	US 2000-246532P	20001108	(60)
	US 2000-249216P	20001117	(60)

US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)

US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 59131

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 15 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:37603 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027248	A1	20030206
APPLICATION INFO.:	US 2001-924340	A1	20010806 (9)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY
RD, SAN DIEGO, CA, 92121

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such
GENSET products may be used as reagents in forensic analyses, as
chromosome markers, as tissue/cell/organelle-specific markers, in the
production of expression vectors. In addition, they may be used in
screening and diagnosis assays for abnormal GENSET expression and/or
biological activity and for screening compounds that may be used in the
treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 16 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:37516 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027161	A1	20030206
APPLICATION INFO.:	US 2001-992600	A1	20011113 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	25529	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such
GENSET products may be used as reagents in forensic analyses, as
chromosome markers, as tissue/cell/organelle-specific markers, in the
production of expression vectors. In addition, they may be used in
screening and diagnosis assays for abnormal GENSET expression and/or
biological activity and for screening compounds that may be used in the
treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.